Drug
Tazarotene clinical trials
Also written Tazorac and IDP-123.
- studies test it
- 41
- open now
- 0
- in phase 3
- 9
- first study started
- 2004
How studies write it
Studies that test it under each name
Development codes
Combined with it in one product
Studies by the year they started
41 studies that test it; most in 2015 (6)
| Year | Studies |
|---|---|
| 2004 | 2 |
| 2005 | 2 |
| 2007 | 2 |
| 2008 | 4 |
| 2009 | 1 |
| 2010 | 3 |
| 2014 | 4 |
| 2015 | 6 |
| 2016 | 6 |
| 2017 | 3 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 7
- Phase 2
- 14
- Phase 3
- 9
- Phase 4
- 7
- No phase
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 24 · Other 17
Bausch Health Americas, Inc. (12) · Stiefel, a GSK Company (3) · Allergan (3) · Jinnah Postgraduate Medical Centre (2) · UCSF Benioff Children's Hospital Oakland (2) · Fougera Pharmaceuticals Inc. (2) · University of Utah (2) · GRI Bio Operations, Inc. (1)
Often tested with
Tested in the same studies.
Halobetasol (9) · Clobetasol (1) · Lotion Dosage Form (1) · Benzoyl Peroxide (1) · Clindamycin (1) · Dapsone (1) · Acitretin (1) · Urea (1)
Studies
Open first, then newest update. How each study uses tazarotene is read from its arms, and is right about nine times in ten.
Testing it · 41
- Safety and Efficacy of IDP-118 in Participants With Plaque PsoriasisCompletedPhase 3Bausch Health Americas, Inc.NCT02462122Written as IDP-118 Lotion
- A Safety and Pharmacokinetics Study of IDP-118 Lotion in Pediatric Participants With Plaque PsoriasisCompletedPhase 4Bausch Health Americas, Inc.NCT03988439Written as IDP-118 Lotion
- Biomarker Modulation and the Inhibition of NKT1 Cells by Oral GRI-0621 in Patients With IPFCompletedPhase 2GRI Bio Operations, Inc.NCT06331624Written as Tazarotene (GRI-0621)
- Topical Tazarotene Vs Placebo In Hand-Foot-Skin ReactionsTerminatedPhase 2Dana-Farber Cancer InstituteNCT04071756Written as Topical Tazarotene
- Anti-Inflammatory Effects of 0.045% Tazarotene/0.01% Halobetasol Lotion in PsoriasisCompletedPhase 4Dermatology Consulting Services, PLLCNCT06042647Written as 0.045% Tazarotene
- Comparison Of Efficacy Of Tazarotene 0.045% Vs Halobetasol Propionate 0.01% Lotion For Treatment of Scalp PsoriasisCompletedNot applicableJinnah Postgraduate Medical CentreNCT06015152Written as Tazarotene 0.045% Topical Application Lotion [ARAZLO]
- Tazarotene 0.045% Lotion for Treating PIE and PIH in Subjects With AcneCompletedPhase 4Dr. Emmy GraberNCT05704114Written as Tazarotene 0.045% Lotion
- Comparing the Efficacy of Topical Tazarotene Gel 0.1% v/s Microneedling in Atrophic Post Acne ScarsCompletedPhase 2/3Jinnah Postgraduate Medical CentreNCT05573425Written as Tazarotene gel 0.1%
- Efficacy of Tazarotene in Treatment of Verruca PlanaStatus unknownPhase 2Zagazig UniversityNCT05314127Written as Tazarotene 0.1% Gel,Top
- A Phase 3, Vehicle-controlled Efficacy and Safety Study of IDP-123 Lotion in the Treatment of Acne Vulgaris (302)CompletedPhase 3Bausch Health Americas, Inc.NCT03168334Written as IDP-123 Lotion
- A Phase 3, Vehicle-controlled Efficacy and Safety Study of IDP-123 Lotion in the Treatment of Acne Vulgaris (301)CompletedPhase 3Bausch Health Americas, Inc.NCT03168321Written as IDP-123 Lotion
- Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the FaceCompletedPhase 2UCSF Benioff Children's Hospital OaklandNCT00489086Written as tazarotene
- Safety and Efficacy of IDP-123 Lotion to Tazorac® Cream, in the Treatment of Acne VulgarisCompletedPhase 2Bausch Health Americas, Inc.NCT02938494Written as IDP-123 Lotion
- Safety and Efficacy of IDP-118 Lotion to Ultravate® in the Treatment of Plaque PsoriasisCompletedPhase 2Bausch Health Americas, Inc.NCT02785172Written as IDP-118 Lotion
- Safety and Efficacy of IDP-118 Lotion in the Treatment of Plaque PsoriasisCompletedPhase 2Bausch Health Americas, Inc.NCT02785159Written as IDP-118 Lotion
- Safety and Efficacy of IDP-118 in the Treatment of Plaque PsoriasisCompletedPhase 3Bausch Health Americas, Inc.NCT02462070Written as IDP-118 Lotion
- Safety and Efficacy of IDP 118 in the Treatment of Plaque PsoriasisCompletedPhase 2Bausch Health Americas, Inc.NCT02045277Written as IDP-118 Lotion
- A Study To Evaluate The Safety And Therapeutic Equivalence of Tazarotene Foam 0.1% in Subjects With Acne VulgarisCompletedPhase 3Actavis Inc.NCT02267746Written as Tazarotene (Fabior™)
- The Effect Of A Controlled Daily Skin Care Regimen On Retinoic Acid ToleranceCompletedNot applicableUniversity of MichiganNCT00440024Written as Tazorac
- Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque PsoriasisCompletedPhase 3Bausch Health Americas, Inc.NCT02462083Written as IDP-118 Lotion
See all 41 studies that test tazarotene →
Given in every arm · 1 — tazarotene is usual care beside what is tested
As the comparator · 2 — what is tested is compared with tazarotene
- A Bioavailability Study of DFD-03 Compared to Tazorac® in Patients With Moderate Acne VulgarisCompletedPhase 2Dr. Reddy's Laboratories LimitedNCT03599193Written as Tazarotene Cream, 0.1%
- Generic Tazarotene Cream, 0.05% for the Treatment of Plaque PsoriasisCompletedPhase 3G & W Laboratories Inc.NCT02160665Written as Reference: Tazorac Cream, 0.05%
Codes
What other systems call tazarotene · ClinicalTrials.gg INT003783
- MeSH (NLM) C086827tazaroteneConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 81BDR9Y8PSTAZAROTENEConfirmed FDA, NLM, Wikidata
- RxNorm 83947Confirmed FDA, Wikidata
- Wikidata Q3981685tazaroteneConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C29487TazaroteneOne source FDA
- DrugBank DB00799One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C086827 | tazarotene | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 81BDR9Y8PS | TAZAROTENE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 83947 | — | Confirmed FDA, Wikidata |
| Wikidata | Q3981685 | tazarotene | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C29487 | Tazarotene | One source FDA |
| DrugBank | DB00799 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.